Clinical Trial Update: A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA [Phase 3]

View source ↗

Summary

Phase 3 safety extension study evaluating benralizumab (MEDI-563) in asthmatic adults and adolescents on ICS + LABA; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2019-02-06